Gene · 4591
Papers1,564
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,564
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Investigation of Regulation and Binding Patterns of the Human Cathelicidin Peptide LL-37 in Complexation with Nucleic Acids, and its Impact on Neutrophil Extracellular Traps. | bioRxiv | 2026 | 41727055 | PubTator, text mining | PubMed |
| Mosaic variegated aneuploidy as a novel feature in patients with Mulibrey nanism and TRIM37 variants. | J Med Genet | 2026 | 41702694 | PubTator, text mining | PubMed |
| Protocol to differentially quantify spatially resolved viral protein-cellular protein interactions via proximity ligation assays. | STAR Protoc | 2026 | 41686640 | PubTator, text mining | PubMed |
| Multi-Omics Dissection of the Role of Ubiquitination Modification in Post-Stroke Neuroinflammation and Function Damage. | Synapse | 2026 | 41676882 | PubTator, text mining | PubMed |
| ASO Visual Abstract: TRIM37 Expression is Associated with Immune Suppression, Poor Response to Neoadjuvant Chemotherapy, and Worse Survival in ER-Positive/HER2-Negative Breast Cancer. | Ann Surg Oncol | 2026 | 41627691 | PubTator, text mining | PubMed |
| Correction to "Circular RNA circRNA_101996 Promoted Cervical Cancer Development by Regulating miR-1236-3p/TRIM37 Axis". | Kaohsiung J Med Sci | 2026 | 41347559 | PubTator, text mining | PubMed |
| ASO Author Reflections: DNA Repair and Tumor Immunity in Breast Cancer: A Context-Dependent Role for TRIM37. | Ann Surg Oncol | 2026 | 41329309 | PubTator, text mining | PubMed |
| TRIM37 Expression is Associated with Immune Suppression Poor Response to Neoadjuvant Chemotherapy and Worse Survival in ER-Positive/HER2-Negative Breast Cancer. | Ann Surg Oncol | 2026 | 41272387 | PubTator, text mining | PubMed |
| Specificity, length and luck drive gene rankings in association studies. | Nature | 2026 | 41193809 | PubTator, text mining | PubMed |
| Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV. | AIDS | 2026 | 41056006 | PubTator, text mining | PubMed |
| TRIM37 recognizes a bipartite degron to ubiquitinate centrosome substrates. | bioRxiv | 2025 | 41446055 | PubTator, text mining | PubMed |
| Multi-criteria group shilling attacks. | PLoS One | 2025 | 41379845 | PubTator, text mining | PubMed |
| Discovery of Potent, Selective and Efficacious Aminopyrazole Inhibitors of PLK4. | J Med Chem | 2025 | 41329867 | PubTator, text mining | PubMed |
| TRIM37-mediated stabilization of PEX5 via monoubiquitination attenuates oxidative stress and demyelination in multiple sclerosis insights from EAE and LPC-induced experimental models. | PLoS One | 2025 | 41134761 | PubTator, text mining | PubMed |
| O-GlcNAcylation of UBAP2L regulates stress granule formation and sunitinib resistance in clear cell renal cell carcinoma. | J Exp Clin Cancer Res | 2025 | 41029457 | PubTator, text mining | PubMed |
| Distal mutations enhance catalysis in designed enzymes by facilitating substrate binding and product release. | Nat Commun | 2025 | 41027962 | PubTator, text mining | PubMed |
| Portal vein stent to save the day. | CVIR Endovasc | 2025 | 40879854 | PubTator, text mining | PubMed |
| Haptoglobin phenotypes and structural variants associate with post-exertional malaise and cognitive dysfunction in myalgic encephalomyelitis. | J Transl Med | 2025 | 40877900 | PubTator, text mining | PubMed |
| Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities. | Mol Cancer | 2025 | 40849651 | PubTator, text mining | PubMed |
| Design, synthesis, and biological evaluation of 5-chlorine-2-amino-pyrimidine derivatives as potent PLK4 inhibitors. | RSC Med Chem | 2025 | 40823488 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4591/papers?page=2